CSI Market
Sign In | Register

Cosciens Biopharma Inc (CSCI) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CSCI Annual Cash Flow →
By examining cash flow figures across successive periods, users can identify shifts in Cosciens Biopharma Inc's cash generation and deployment strategy.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		0 0 0 (Dec 31 2024)
Operating Activities
Income-10.35
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss PropertyPlant And0.24
Share-based Compensation0.00
Income (Loss) from Equity Method Investments-0.20
Financial Instruments and Foreign Currency Transaction0.00
Gain On Modification Of Building Lease-
Adjustments For Depreciation And Amortisation Expense-
Adjustments For Sharebased Payments-
Adjustments For Employee Future Benefits-
Adjustments For Amortization Of Deferred Income-
Gains Losses On Disposals Of Property Plant And Equipment-
Other Adjustments For Noncash Items-
Interest Accretion On Lease Liability-
Income Taxes Paid Refund-
Increase Decrease In Working Capitals-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Accounts Payable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.01
Discontinued operations0.00
Net Cash flow from Operating Activities-8.47
Investing Activities
Capital Expenditures0.71
Sale of Capital Items0.24
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Cash Flows From Used In Decrease Increase In Restricted Cash And Cash Equivalents-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.46
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.41
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.41
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-7.52
Total Cash Flow16.39
4 historic quarters locked

Sign in to unlock the full Cosciens Biopharma Inc cash flow history.

Sign In Create Free Account

About Cosciens Biopharma Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

  • Form: 20-F (Period: 20251231)
  • Filed with the SEC: March 25, 2026
  • Source: form20-f.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-012703

Figures are derived from filed reports and may be restated. Historical data is subject to revision.